 |
|
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Naoshi Nishida
Clin Mol Hepatol. 2025;31(1):311-315. Published online 2024 Sep 3 DOI: https://doi.org/10.3350/cmh.2024.0739
|
|
Citations to this article as recorded by
 Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee
Clinical and Molecular Hepatology.2025; 31(1): e84. CrossRef T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells
Thikra Majid Muhammed, Saade Abdalkareem Jasim, Ahmed Hussein Zwamel, Safia Obaidur Rab, Suhas Ballal, Abhayveer Singh, Anima Nanda, Subhashree Ray, Ahmed Hjazi, Hatif Abdulrazaq Yasin
Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub] CrossRef Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”
Naoshi Nishida
Clinical and Molecular Hepatology.2025; 31(2): 635. CrossRef Addressing the Complexities of Pre-Liver Transplant Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Response to Recent Commentaries
Mohammad Saeid Rezaee-Zavareh, Zhiyong Guo, Ju Dong Yang
Journal of Hepatology.2024;[Epub] CrossRef
|